Peter Riedell, MD, University of Chicago Medicine, Chicago, IL, discusses the use of CAR T-cell therapies for patients with aggressive B-cell lymphomas, including tisagenlecleucel and axicabtagene ciloleucel, both approved by the FDA in the third line setting for patients with aggressive B-cell lymphomas. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).